New Rapid Response® Orphine Test Strip

Highlights:

Originally discovered in the 1960s, this class of synthetic opioids entered the illicit drug market in 2019.
Following China's class-wide scheduling of nitazene compunds in July 2025, orphine analogues have proliferated in the illicit drug supply a pattern consistent with the earlier shift from fentanyl to nitazenes.
The Rapid Response^® Orphine Test Strip detects orphine and orphine analogues in liquid/powder samples, with a cut-off of 2000ng/mL.
Orphine Test Strips are available to order from BTNX and Lochness Medical Supplies.
Microscoops are included in each individually sealed test strip.
A QR code is printed on the back of every test strip pouch for access to resources and tutorial videos.
Contact us to order now Canada, USA

Introduction

Orphines are a class of synthetic opioids originally developed in Belgium in the 1960s for their potent anaesthetic properties and later withdrawn from clinical use due to their overdose risk. It is now increasingly found in the illicit drug supply, with some analogues having comparable to substantially more potency levels than fentanyl. Brorphine was the first member reported in the illicit drug market in 2019, and additional analogues, including cychlorphine and spirochlorphine, have emerged more recently. Following China's class-wide scheduling of nitazene compounds in July 2025, orphine analogues have proliferated in the illicit drug supply a pattern consistent with the earlier shift from fentanyl to nitazenes.

In the United States and Canada, orphines have been detected in samples sold as other opioids, such as hydromorphone and oxycodone, that contained no other active drug. As with other potent synthetic opioids, even small amounts of orphines can cause respiratory depression, and unknowingly consuming orphine-containing substances increases the risk of accidental overdose. Early evidence suggests that existing fentanyl and nitazene test strips do not reliably detect orphines, creating a gap in point-of-use drug checking that this test strip is designed to address.

About Rapid Response® Orphine Test Strip

The Rapid Response® Orphine Test Strip from BTNX is specifically designed for the swift screening of Orphines and Orphine analogues in liquid/powder samples. The test incorporates an antibody that selectively identifies orphine and orphine analogues from other substances. Like other harm reduction test strips, it operates on a competitive binding principle and generates a colorimetric result. If any of the listed orphine substances are present in the sample at a concentration surpassing the designated cut-off, a singular-colored line will appear in the test.

Results Interpretation

Positive - Orphine Detected

Only one coloured line appears in the control region (C). No apparent coloured line appears in the test region (T).

Negative - Orphine Could Not Be Detected

Two coloured lines appear on the membrane. One line appears in the control region (C) and another line appears in the test region (T).

Test Performance

Analytical Sensitivity

The following compounds were individually spiked into water to evaluate the detection capability of the Rapid Response® Orphine Test Strip. The cut-off listed in the table represents the concentration at which a substance will begin to show a mix of positive and negative results.

Compounds	Cut Off
N-Propionitrile Chlorphine	2000 ng/mL

Analytical Specificity

The following compounds were spiked into water at the concentrations shown to examine possible cross-reactivity with the Rapid Response® Orphine Test Strip. None produced a false-positive result.

Compounds	Concentration	Result
Xylazine	10 mg/mL	Negative
Diphenhydramine	10 mg/mL	Negative
Caffeine	5 mg/mL	Negative
Lidocaine	10 mg/mL	Negative
Phenacetin	0.1 mg/mL	Negative
Levamisole	10 mg/mL	Negative
Acetaminophen	10 mg/mL	Negative
Dimethylsulphone	10 mg/mL	Negative

Ordering Information

The Rapid Response® Orphine Test Strip (Liquid / Powder) is available to order under the product code ORP-18S26-100 from Lochness Medical Supplies in the USA, and BTNX Inc. in Canada and the international market.